Abstract
Background
A previous phase II study showed that S-1 (TS-1®) was effective for advanced gastric cancers and had mild toxicity. The present study aimed to evaluate the efficacy and feasibility of this novel anticancer drug combined with low-dose cisplatin (CDDP).
Methods
Fifteen patients with unresectable and recurrent gastric cancer were enrolled. S-1 was administered orally twice daily after meals, at a standard dose of 80 mg/m2 per day according to the late phase II trial protocol. One course consisted of 28 days' consecutive administration followed by 14 days' rest. Five or 10 mg CDDP was infused three times each week (days 1, 3, 5) during S-1 administration on hospitalization, and once each week (day 1) at the outpatient clinic. Patients' backgrounds, response rates, response durations, and time to progression were investigated.
Results
None of the 15 patients had a complete response and 8 had a partial response. Therefore, the overall response rate was 53% (8/15). For site efficacy, the response rate was 50% (5/10) for the primary lesion, 50% (3/6) for liver metastasis, and 39% (5/13) for lymph node metastasis. The median response duration of the 8 responders was 4 months, and the time to progression was 3.3 months. Adverse reactions appeared in 60% (9/15). The incidence of adverse reactions of grades 3 and 4 was 13% (2/15) and 0%, respectively. As for hematological toxicity, grade 3 leukopenia was observed in 2 patients (2/15), but decreased hemoglobin level and thrombocytopenia did not appear. Although gastrointestinal adverse reactions appeared in 40% (6/15), all reactions were grades 1 and 2. Because of the mild toxicity, most patients were treated at the outpatient clinic.
Conclusions
Combination chemotherapy of S-1 and low-dose CDDP is expected to be a useful chemotherapy for advanced gastric cancer.
Article PDF
Similar content being viewed by others
References
DP Kelsen (1995) Cancer of the stomach VT DeVita (Eds) Cancer, principles and practice of oncology EditionNumber4th Ed. JB Lippincott Philadelphia 838–48
J Wils (1996) ArticleTitleThe treatment of advanced gastric cancer Semin Oncol 23 397–406 Occurrence Handle8658224 Occurrence Handle1:STN:280:BymB2czgtVM%3D
Y Sakata H Suzuki (1995) ArticleTitleDo we have a strategy for gastrointestinal cancers at present and the future? Cancer Chemother 10 169–80
CG Moertel (1977) Chemotherapy of gastrointestinal cancer HJ Tagnon MJ Staquest (Eds) Recent advances in cancer treatment Raven New York 311–23
M Beer G Cocconi G Ceci M Varini FA Cavalli (1983) ArticleTitlephase II study of cisplatin in advanced gastric cancer Eur J Cancer Clin Oncol 19 717–20 Occurrence Handle6683644 Occurrence Handle10.1016/0277-5379(83)90003-2 Occurrence Handle1:STN:280:BiyB283gtFE%3D
K Miyamoto S Yoshida D Saito Y Shimada H Tajiri H Yamaguchi et al. (1990) ArticleTitlePilot phase II study of cis-diaminedichloroplatinum (II) against metastatic gastric cancers Jpn J Clin Oncol 20 169–76 Occurrence Handle2370696 Occurrence Handle1:STN:280:By%2BA3Mjpt1U%3D
HO Klein P Dias Wickramanayake F Dieterle R Mohr H Oerkermann J Brock et al. (1982) ArticleTitleChemotherapieprotokoll zur behandlung des metastasierenden Magenkarzinoms. Methitrexat, Adriamycin, und 5-fluorouracil Dtsch Med Wochenschr 107 1708–12 Occurrence Handle7140549 Occurrence Handle1:STN:280:BiyD2M3os1w%3D Occurrence Handle10.1055/s-2008-1070192
A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe et al. (1997) ArticleTitleRandomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubin, and methotrexate in esophagogastric cancer J Clin Oncol 15 261–7 Occurrence Handle8996151 Occurrence Handle1:CAS:528:DyaK2sXnsV2msA%3D%3D
JA Wils HO Klein DJT Wagerer H Bleiberg H Reis F Korsten et al. (1991) ArticleTitleSequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of gastric cancer: a trial of the EORTG J Clin Oncol 9 827–31 Occurrence Handle2016625 Occurrence Handle1:STN:280:By6B3c3itV0%3D
D Kelsen OT Atiq L Saltz D Niedzwiecki D Ginn D Chapman et al. (1992) ArticleTitleFAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer J Clin Oncol 10 541–8 Occurrence Handle1548519 Occurrence Handle1:STN:280:By2C1Mzps1U%3D
P Preusser H Wilke W Achterrath U Fink L Lenaz A Heinicke et al. (1989) ArticleTitlePhase II study with the combination of etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer J Clin Oncol 7 1310–17 Occurrence Handle2671287 Occurrence Handle1:STN:280:BiaA287ls1I%3D
A Lerner R Gonin GD Steele SuffixJr J Mayer (1992) ArticleTitleEtoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial J Clin Oncol 10 536–40 Occurrence Handle1548518 Occurrence Handle1:STN:280:By2C1Mzps1Q%3D
AJ Lacave FJ Baron LM Anton E Estrada LM De Sande I Palacio et al. (1991) ArticleTitleCombination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial Ann Oncol 2 751–4 Occurrence Handle1801881 Occurrence Handle1:STN:280:By2C1Mfot10%3D
P Rougier M Ducreux M Mahjoubi JP Pignon S Bellefqih J Oliveira et al. (1994) ArticleTitleEfficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas: a phase II trial with prognostic factor analysis Eur J Cancer 30 1263–9
U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave EV Cutsem et al. (2000) ArticleTitleFinal results of randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the EORTG J Clin Oncol 18 2648–57 Occurrence Handle10894863 Occurrence Handle1:CAS:528:DC%2BD3cXls12iurk%3D
T Shirasaka K Nakano T Takechi H Satake J Uchida A Fujioka et al. (1996) ArticleTitleAntitumor activity of 1 M tegafur — 0.4 M 5-chloro-2,4-dihydroxypyridine — 1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 2602–6 Occurrence Handle8653704 Occurrence Handle1:CAS:528:DyaK28XjtlCgurg%3D
T Shirasaka S Shimamoto H Ohshimo M Yamaguchi T Kato K Yonekura et al. (1996) ArticleTitleDevelopment of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548–57 Occurrence Handle8862723 Occurrence Handle1:CAS:528:DyaK28Xltleru78%3D
T Takechi K Nakano J Uchida A Mita K Toko S Takeda et al. (1997) ArticleTitleAntitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats Cancer Chemother Pharmacol 39 205–11 Occurrence Handle8996521 Occurrence Handle1:CAS:528:DyaK2sXis1ajsL4%3D
K Sugimachi Y Maehara N Horikoshi Y Shimada Y Sakata Y Mitachi et al. (1999) ArticleTitleAn early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers Oncology 57 202–10 Occurrence Handle10545788 Occurrence Handle10.1159/000012032 Occurrence Handle1:CAS:528:DyaK1MXmvF2msr0%3D
Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi (1998) ArticleTitleLate phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur — 0.4 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715–20 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D
Japanese Gastric (1998) ArticleTitleCancer Association. Japanese classification of gastric carcinoma, 2nd English edition Gastric Cancer 1 10–24
InstitutionalAuthorNameWorld Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48 World Health Organization Geneva
BibInstitutionalEditorNameJapanese Research Society for Gastric Cancer (Eds) (1995) Japanese classification of gastric carcinoma EditionNumber1st English Ed. Kanehara Tokyo
K Tobinai A Kohno Y Shimada T Watanabe T Tamura K Takeyama et al. (1993) ArticleTitleToxicity grading criteria of Japan Clinical Oncology Group Jpn J Clin Oncol 23 250–7 Occurrence Handle8411739 Occurrence Handle1:STN:280:ByuD3Mjisl0%3D
Y Shimada K Shirao A Ohtsu I Hyodo H Saito N Yamanishi et al. (1999) ArticleTitlePhase III study of UFT + MMC versus 5-FU + CDDP versus 5-FU alone in patients with advanced gastric cancer Proc Am Soc Clin Oncol 18 1043
YS Chung Y Yamashita B Nakata A Nitta T Inoue K Hirayama et al. (1995) ArticleTitleCombination therapy of 5-FU and low dose CDDP for advanced and recurrent gastric cancer Jpn J Cancer Chemother 22 149–51 Occurrence Handle1:STN:280:ByqC38nmt1I%3D
W Koizumi M Kurihara S Nakano K Hasegawa (2000) ArticleTitlePhase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191–7 Occurrence Handle10765119 Occurrence Handle10.1159/000012099 Occurrence Handle1:CAS:528:DC%2BD3cXjvVeitr4%3D
Y Saikawa T Kanai Y Kawano Y Otani T Kubota M Kitajima (2002) ArticleTitleA novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer Jpn J Cancer Chemother 29 1241–5
T Gomi M Ohtoshi N Tamaki H Momoi S Kanaya T Katayama et al. (2002) ArticleTitleThree cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatin Jpn J Cancer Chemother 29 301–4
T Kamata Y Hayashi G Minatoya Y Michiwa I Onishi T Takeda et al. (2001) ArticleTitleA pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer Jpn J Cancer Chemother 28 1419–22 Occurrence Handle1:STN:280:DC%2BD3Mrntl2itw%3D%3D
T Iwazawa M Kinuta H Yano S Matsui S Tamagaki A Yasue et al. (2002) ArticleTitleAn oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resection Gastric Cancer 5 96–101 Occurrence Handle12111585 Occurrence Handle10.1007/s101200200016
A Ohtsu N Boku F Nagashima W Koizumi S Tanabe K Saigenji et al. (2001) ArticleTitleA phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer (abstract) Proc Am Soc Clin Oncol 20 165
Y Yonemura T Sawa K Kinoshita N Matsuki S Fushida S Tanaka et al. (1993) ArticleTitleNeoadjuvant chemotherapy for high-grade advanced gastric cancer World J Surg 17 256–61 Occurrence Handle8511923 Occurrence Handle10.1007/BF01658939 Occurrence Handle1:STN:280:ByyB1cbns10%3D
T Nakajima K Ota S Ishihara S Oyama M Nishi Y Ohashi et al. (1997) ArticleTitleCombined intensive chemotherapy and radical surgery for incurable gastric cancer Ann Surg Oncol 4 203–8 Occurrence Handle9142380 Occurrence Handle1:STN:280:ByiB1cjivVw%3D
T Yoshikawa M Kanari A Tsuburaya O Kobayashi M Sairenji H Motohashi et al. (2000) ArticleTitleAdvanced gastric carcinoma successfully treated with TS-1 as neoadjuvant chemotherapy Gastric Cancer 3 171–5 Occurrence Handle11984733
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsujitani, S., Fukuda, K. & Kaibara, N. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer. Gastric Cancer 6 (Suppl 1), 50–57 (2003). https://doi.org/10.1007/s10120-003-0223-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-003-0223-x